Literature DB >> 15827181

Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections.

Cameron P Simmons1, Tao Dong, Nguyen Vinh Chau, Nguyen Thi Phuong Dung, Tran Nguyen Bich Chau, Le Thi Thu Thao, Nguyen Thi Dung, Tran Tinh Hien, Sarah Rowland-Jones, Jeremy Farrar.   

Abstract

T-cell responses to dengue viruses may be important in both protective immunity and pathogenesis. This study of 48 Vietnamese adults with secondary dengue virus infections defined the breadth and magnitude of peripheral T-cell responses to 260 overlapping peptide antigens derived from a dengue virus serotype 2 (DV2) isolate. Forty-seven different peptides evoked significant gamma interferon enzyme-linked immunospot (ELISPOT) assay responses in 39 patients; of these, 34 peptides contained potentially novel T-cell epitopes. NS3 and particularly NS3200-324 were important T-cell targets. The breadth and magnitude of ELISPOT responses to DV2 peptides were independent of the infecting dengue virus serotype, suggesting that cross-reactive T cells dominate the acute response during secondary infection. Acute ELISPOT responses were weakly correlated with the extent of hemoconcentration in individual patients but not with the nadir of thrombocytopenia or overall clinical disease grade. NS3556-564 and Env414-422 were identified as novel HLA-A*24 and B*07-restricted CD8+ T-cell epitopes, respectively. Acute T-cell responses to natural variants of Env414-422 and NS3556-564 were largely cross-reactive and peaked during disease convalescence. The results highlight the importance of NS3 and cross-reactive T cells during acute secondary infection but suggest that the overall breadth and magnitude of the T-cell response is not significantly related to clinical disease grade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827181      PMCID: PMC1082776          DOI: 10.1128/JVI.79.9.5665-5675.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction.

Authors:  R S Lanciotti; C H Calisher; D J Gubler; G J Chang; A V Vorndam
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones.

Authors:  I Kurane; M A Brinton; A L Samson; F A Ennis
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

3.  Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever.

Authors:  D B Bethell; J Gamble; P L Pham; M D Nguyen; T H Tran; T H Ha; T N Tran; T H Dong; I B Gartside; N J White; N P Day
Journal:  Clin Infect Dis       Date:  2001-01-15       Impact factor: 9.079

4.  Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue.

Authors:  I Kurane; B L Innis; S Nimmannitya; A Nisalak; A Meager; J Janus; F A Ennis
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

5.  Nutritional status of children with dengue hemorrhagic fever.

Authors:  U Thisyakorn; S Nimmannitya
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

6.  Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine.

Authors:  T Dharakul; I Kurane; N Bhamarapravati; S Yoksan; D W Vaughn; C H Hoke; F A Ennis
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

Review 7.  Dengue: the risk to developed and developing countries.

Authors:  T P Monath
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

8.  Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination.

Authors:  S Green; I Kurane; R Edelman; C O Tacket; K H Eckels; D W Vaughn; C H Hoke; F A Ennis
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.

Authors:  N Sangkawibha; S Rojanasuphot; S Ahandrik; S Viriyapongse; S Jatanasen; V Salitul; B Phanthumachinda; S B Halstead
Journal:  Am J Epidemiol       Date:  1984-11       Impact factor: 4.897

10.  Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses.

Authors:  J Blok; S M McWilliam; H C Butler; A J Gibbs; G Weiller; B L Herring; A C Hemsley; J G Aaskov; S Yoksan; N Bhamarapravati
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

View more
  77 in total

1.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

Review 2.  Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis.

Authors:  Karen Clyde; Jennifer L Kyle; Eva Harris
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

3.  A systematic bioinformatics approach for selection of epitope-based vaccine targets.

Authors:  Asif M Khan; Olivo Miotto; A T Heiny; Jerome Salmon; K N Srinivasan; Eduardo J M Nascimento; Ernesto T A Marques; Vladimir Brusic; Tin Wee Tan; J Thomas August
Journal:  Cell Immunol       Date:  2007-04-16       Impact factor: 4.868

4.  Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals.

Authors:  Joseph D Comber; Aykan Karabudak; Xiaofang Huang; Paolo A Piazza; Ernesto T A Marques; Ramila Philip
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination.

Authors:  Lauren E Yauch; Tyler R Prestwood; Monica M May; Malika M Morar; Raphaël M Zellweger; Bjoern Peters; Alessandro Sette; Sujan Shresta
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

6.  Structural Basis for CD4+ T Cell Epitope Dominance in Arbo-Flavivirus Envelope Proteins: A Meta-Analysis.

Authors:  Samuel J Landry; Daniel L Moss; Da Cui; Ryan P Ferrie; Mitchell L Fullerton; Evan A Wells; Lu Yang; Nini Zhou; Thomas Dougherty; Ramgopal R Mettu
Journal:  Viral Immunol       Date:  2017-06-14       Impact factor: 2.257

7.  Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design.

Authors:  Rosa Ramírez; Rosabel Falcón; Alienys Izquierdo; Angélica García; Mayling Alvarez; Ana Beatriz Pérez; Yudira Soto; Mayra Muné; Emiliana Mandarano da Silva; Oney Ortega; Ronaldo Mohana-Borges; María G Guzmán
Journal:  Virus Genes       Date:  2014-05-23       Impact factor: 2.332

Review 8.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

9.  Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.

Authors:  Laura Rivino; Emmanuelle A P Kumaran; Vojislav Jovanovic; Karen Nadua; En Wei Teo; Shyue Wei Pang; Guo Hui Teo; Victor Chih Hao Gan; David C Lye; Yee Sin Leo; Brendon J Hanson; Kenneth G C Smith; Antonio Bertoletti; David M Kemeny; Paul A MacAry
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

10.  Identification of major histocompatibility complex restriction and anchor residues of foot-and-mouth disease virus-derived bovine T-cell epitopes.

Authors:  Wilhelm Gerner; Sabine E Hammer; Karl-Heinz Wiesmüller; Armin Saalmüller
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.